Evidence map›Paper›PMID 29397376›Full record

Trial reportThe lancet. Diabetes & endocrinology2018

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.

Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen, SUSTAIN 7 investigators

4 registry-linked trialsAbstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in The lancet. Diabetes & endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02648204. Cited by 376 papers, 21 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
376citing papers in PubMed, 21 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02648204 phase3completed

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes

Ran2016Enrolled1,201Registered outcomes28Posted comparisons6ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsDulaglutide, semaglutide
PMID 29764222PMID 30615985PMID 29246950PMID 30362224PMID 30865526PMID 31168765PMID 29557057PMID 30927241other papers from this trial
Open the trial in the graph
NCT05136287 completedstarted 2022, after this paper: background citation

Semaglutide versus glp-1 receptor agonists. effectiveness , safety and quality of life in patients with diabetes mellitus 2. observational, prospective and multicenter study. several study.

Ran2022Enrolled140Registered outcomes7Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Quality of Life, Safety Issues, Weight LossArmsGLP-1 receptor agonist
PMID 27295427PMID 19545590PMID 33567185PMID 23882037PMID 36520578PMID 8366922PMID 20609967PMID 26378978PMID 28249135PMID 31189511PMID 9742976other papers from this trial
Open the trial in the graph
NCT06894784 phase3recruitingstarted 2025, after this paper: background citation

Semaglutide And Empagliflozin Combination Therapy Added To Automated Insulin Delivery In Adults With Type 1 Diabetes (SEMPA)

Ran2025Enrolled36Registered outcomes13Posted comparisons0ConditionsDiabetes Type 1ArmsIntervention Period 1: Semaglutide + Empagliflozin, Intervention Period 2: Semaglutide + Empagliflozin Placebo, Intervention Period 3: Semaglutide Placebo + Empagliflozin, Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo
PMID 20616619PMID 36942888PMID 31539622PMID 29246950PMID 27295427PMID 28854085PMID 25388240PMID 24947583PMID 27633186PMID 30833170PMID 10233049PMID 19925391other papers from this trial
Open the trial in the graph
NCT06686134 recruitingnot on this mapstarted 2024, after this paper: background citation

Comprehensive Clinical Evaluation Study of GLP-1RA

TypeobservationalSponsorLI YANRan2024 to 2026Enrolled492ConditionsT2DM
3 · Its place in the literature

Who cites it

376 citing papers in PubMed, 21 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025 · on this map
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Comparative effectiveness of semaglutideFrontiers in pharmacology · 2025
    Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Clinical Pharmacokinetics of Semaglutide: A Systematic Review.Drug design, development and therapy · 2024
    Pooled it
  19. Pooled it
  20. Pooled it

316 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Richard E PratleyFlorida Hospital Translational Research Institute for Metabolism and Diabetes, Orlando, FL, USA. Electronic address: richard.pratley@flhosp.org.
Vanita R ArodaMedStar Health Research Institute, Hyattsville, MD, USA.
Ildiko LingvayUT Southwestern Medical Center, Dallas, TX, USA.
Jörg Lüdemanndiabetes-falkensee, Diabetes Centre and Centre for Clinical Studies, Falkensee, Germany.
Camilla AndreassenNovo Nordisk, Søborg, Denmark.
Andrea NavarriaNovo Nordisk, Søborg, Denmark.
Adie ViljoenLister Hospital, Stevenage, UK.
SUSTAIN 7 investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite common mechanisms of actions, glucagon-like peptide-1 receptor agonists differ in structure, pharmacokinetic profile, and clinical effects. This head-to-head trial compared semaglutide with dulaglutide in patients with inadequately controlled type 2 diabetes.

methodsThis was an open-label, parallel-group, phase 3b trial done at 194 hospitals, clinical institutions or private practices in 16 countries. Eligible patients were aged 18 years or older and had type 2 diabetes with HbA

findingsBetween Jan 6, 2016, and June 22, 2016, 1201 patients were randomly assigned to treatment; of these, 301 were exposed to semaglutide 0·5 mg, 299 to dulaglutide 0·75 mg, 300 to semaglutide 1·0 mg, and 299 to dulaglutide 1·5 mg. 72 (6%) patients withdrew from the trial (22 receiving semaglutide 0·5 mg, 13 receiving dulaglutide 0·75 mg, 21 receiving semaglutide 1·0 mg, and 16 receiving dulaglutide 1·5 mg). From overall baseline mean, mean percentage HbA

interpretationAt low and high doses, semaglutide was superior to dulaglutide in improving glycaemic control and reducing bodyweight, enabling a significantly greater number of patients with type 2 diabetes to achieve clinically meaningful glycaemic targets and weight loss, with a similar safety profile.

fundingNovo Nordisk.

Indexed as

Blood GlucoseBody WeightDiabetes Mellitus, Type 2FemaleGlucagon-Like PeptidesHumansHypoglycemic AgentsImmunoglobulin Fc FragmentsMaleMiddle AgedPrognosisRecombinant Fusion ProteinsSemaglutideBlood GlucosedulaglutideGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsSemaglutide

Identifiers

PMID29397376

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.